General Information of the Protein
Protein ID
PT03168
Protein Name
Proteasome subunit beta type-8
Secondarily
Protein Name
Low molecular mass protein 7
Macropain subunit C13
Multicatalytic endopeptidase complex subunit C13
Proteasome component C13
Proteasome subunit beta-5i
Really interesting new gene 10 protein
Gene Name
PSMB8
Secondarily
Gene Name
LMP7
PSMB5i
RING10
Y2
Sequence
MALLDVCGAPRGQRPESALPVAGSGRRSDPGHYSFSMRSPELALPRGMQPTEFFQSLGGDGERNVQIEMAHGTTTLAFKFQHGVIAAVDSRASAGSYISALRVNKVIEINPYLLGTMSGCAADCQYWERLLAKECRLYYLRNGERISVSAASKLLSNMMCQYRGMGLSMGSMICGWDKKGPGLYYVDEHGTRLSGNMFSTGSGNTYAYGVMDSGYRPNLSPEEAYDLGRRAIAYATHRDSYSGGVVNMYHMKEDGWVKVESTDVSDLLHQYREANQ
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Protease
>
Threonine protease
>
Threonine protease PBT clan
>
Threonine protease T1A subfamily
Function
The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Involved in the generation of spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein (PubMed:27049119). Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes.
    Show/Hide
Uniprot ID
Primary ID:
P28062

Secondarily ID:
B0UZC0
Q29824
Q5JNW6
Q5QNR8
Q96J48
    Show/Hide
Ensembl ID
ENSG00000204264
HGNC ID
HGNC:9545
Subcellular Location
Cytoplasm
Nucleus
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000626 , Karpas-1106P
Compound ID Compound Name Compound Formula
CP0955534
(S)-2-(2-(1H-indol-3-yl)-2-oxoacetamido)-N4-tert-butyl-N1-((S)-1-(naphthalen-1-ylmethylamino)-1-oxopropan-2-yl)succinamide
   Show/Hide
C32H35N5O5
 1
1
IC50 = 15 nM
   TI
   LI
   LO
   TS
CP0363571
(2S)-N'-tert-butyl-N-[(2S)-1-[(4-fluoronaphthalen-1-yl)methylamino]-1-oxopropan-2-yl]-2-[(4-methylphenyl)sulfonylamino]pentanediamide
   Show/Hide
C30H37FN4O5S
 1
1
IC50 = 24 nM
   TI
   LI
   LO
   TS
CP0354052
(2S)-N'-tert-butyl-N-[(2S)-1-[(4-fluoronaphthalen-1-yl)methylamino]-3-methoxy-1-oxopropan-2-yl]-2-[(4-methylphenyl)sulfonylamino]pentanediamide
   Show/Hide
C31H39FN4O6S
 1
1
IC50 = 28 nM
   TI
   LI
   LO
   TS
CP0574852
(2S)-N'-tert-butyl-N-[(2S)-1-[(4-fluoronaphthalen-1-yl)methylamino]-1-oxopropan-2-yl]-2-(3-phenylpropanoylamino)pentanediamide
   Show/Hide
C32H39FN4O4
 1
1
IC50 = 39 nM
   TI
   LI
   LO
   TS
CP0560194
(2S)-N'-tert-butyl-N-[(2S)-1-[(4-fluoronaphthalen-1-yl)methylamino]-1-oxopropan-2-yl]-2-[(5-methyl-1,2-oxazole-3-carbonyl)amino]pentanediamide
   Show/Hide
C28H34FN5O5
 1
1
IC50 = 53 nM
   TI
   LI
   LO
   TS
CP0354051
(2S)-N'-tert-butyl-N-[(2S)-1-[(4-fluoronaphthalen-1-yl)methylamino]-3-methoxy-1-oxopropan-2-yl]-2-[(4-methylphenyl)sulfonylamino]butanediamide
   Show/Hide
C30H37FN4O6S
 1
1
IC50 = 197 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0213895
Kzr-616
   Show/Hide
C30H42N4O8
 1
1 IC50 = 0.039 nM
CP0354052
(2S)-N'-tert-butyl-N-[(2S)-1-[(4-fluoronaphthalen-1-yl)methylamino]-3-methoxy-1-oxopropan-2-yl]-2-[(4-methylphenyl)sulfonylamino]pentanediamide
   Show/Hide
C31H39FN4O6S
 1
1 IC50 = 0.8 nM
CP0560194
(2S)-N'-tert-butyl-N-[(2S)-1-[(4-fluoronaphthalen-1-yl)methylamino]-1-oxopropan-2-yl]-2-[(5-methyl-1,2-oxazole-3-carbonyl)amino]pentanediamide
   Show/Hide
C28H34FN5O5
 1
1 IC50 = 1.2 nM
CP0574852
(2S)-N'-tert-butyl-N-[(2S)-1-[(4-fluoronaphthalen-1-yl)methylamino]-1-oxopropan-2-yl]-2-(3-phenylpropanoylamino)pentanediamide
   Show/Hide
C32H39FN4O4
 1
1 IC50 = 1.6 nM
CP0571153
US10294246, Compound No. 132
   Show/Hide
C18H19BClNO4
 1
1 IC50 = 1.8 nM
CP0564533
[(1R)-2-(1-benzofuran-3-yl)-1-(3-methoxypropanoylamino)ethyl]boronic acid
   Show/Hide
C14H18BNO5
 1
1 IC50 = 1.9 nM
CP0571391
US10294246, Compound No. 18
   Show/Hide
C16H16BN3O4
 1
1 IC50 = 1.9 nM
CP0545536
US10294246, Compound No. 6
   Show/Hide
C18H18BNO4
 1
1 IC50 = 2.1 nM
CP0550598
US10294246, Compound No. 92
   Show/Hide
C19H20BNO5
 1
1 IC50 = 2.2 nM
CP0570106
US10294246, Compound No. 20
   Show/Hide
C16H16BN3O4
 1
1 IC50 = 2.3 nM
CP0575635
US10294246, Compound No. 8
   Show/Hide
C17H17BN2O4
 1
1 IC50 = 2.3 nM
CP0363571
(2S)-N'-tert-butyl-N-[(2S)-1-[(4-fluoronaphthalen-1-yl)methylamino]-1-oxopropan-2-yl]-2-[(4-methylphenyl)sulfonylamino]pentanediamide
   Show/Hide
C30H37FN4O5S
 1
1 IC50 = 2.4 nM
CP0550599
US10294246, Compound No. 134
   Show/Hide
C19H18BClN2O4
 1
1 IC50 = 2.9 nM
CP0547335
US10294246, Compound No. 125
   Show/Hide
C18H17BFNO4
 1
1 IC50 = 3.1 nM
CP0564531
US10294246, Compound No. 105
   Show/Hide
C19H19BN2O4
 1
1 IC50 = 3.1 nM
CP0571390
US10294246, Compound No. 124
   Show/Hide
C19H22BNO4
 1
1 IC50 = 3.1 nM
CP0545538
[(1R)-2-(1-benzofuran-3-yl)-1-[[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptane-2-carbonyl]amino]ethyl]boronic acid
   Show/Hide
C17H20BNO5
 1
1 IC50 = 3.6 nM
CP0576763
[(1R)-2-(1-benzofuran-3-yl)-1-[(2-pyrazol-1-ylacetyl)amino]ethyl]boronic acid
   Show/Hide
C15H16BN3O4
 1
1 IC50 = 3.7 nM
CP0569314
US10294246, Compound No. 85
   Show/Hide
C18H17BClNO4
 1
1 IC50 = 4.1 nM
CP0572729
US10294246, Compound No. 130
   Show/Hide
C20H21BN2O4
 1
1 IC50 = 4.4 nM
CP0575641
US10294246, Compound No. 75
   Show/Hide
C19H20BNO4
 1
1 IC50 = 4.5 nM
CP0955534
(S)-2-(2-(1H-indol-3-yl)-2-oxoacetamido)-N4-tert-butyl-N1-((S)-1-(naphthalen-1-ylmethylamino)-1-oxopropan-2-yl)succinamide
   Show/Hide
C32H35N5O5
 1
1 IC50 = 5 nM
CP0575644
US10294246, Compound No. 90
   Show/Hide
C19H17BN2O4
 1
1 IC50 = 5.2 nM
CP0564529
[(1R)-2-(1-benzofuran-3-yl)-1-[[(2R)-oxolane-2-carbonyl]amino]ethyl]boronic acid
   Show/Hide
C15H18BNO5
 1
1 IC50 = 5.9 nM
CP0550601
[(1R)-2-(1-benzofuran-3-yl)-1-[(2-methoxyacetyl)amino]ethyl]boronic acid
   Show/Hide
C13H16BNO5
 1
1 IC50 = 6 nM
CP0572728
US10294246, Compound No. 126
   Show/Hide
C19H19BClNO4
 1
1 IC50 = 6.4 nM
CP0547336
[(1R)-2-(1-benzofuran-3-yl)-1-[[(3R)-oxolane-3-carbonyl]amino]ethyl]boronic acid
   Show/Hide
C15H18BNO5
 1
1 IC50 = 10 nM
CP0570105
US10294246, Compound No. 19
   Show/Hide
C17H17BN2O4
 1
1 IC50 = 11 nM
CP0575636
[(1R)-2-(1-benzofuran-3-yl)-1-[[(1R,2S,4S)-7-oxabicyclo[2.2.1]heptane-2-carbonyl]amino]ethyl]boronic acid
   Show/Hide
C17H20BNO5
 1
1 IC50 = 15 nM
CP0564532
[(1R)-1-acetamido-2-(1-benzofuran-3-yl)ethyl]boronic acid
   Show/Hide
C12H14BNO4
 1
1 IC50 = 18 nM
CP0545537
[(1R)-2-(1-benzofuran-3-yl)-1-[[(3S)-oxolane-3-carbonyl]amino]ethyl]boronic acid
   Show/Hide
C15H18BNO5
 1
1 IC50 = 28 nM
CP0579795
US10294246, Compound No. 110
   Show/Hide
C18H18BNO4
 1
1 IC50 = 29 nM
CP0062987
(2S)-3-(4-methoxyphenyl)-N-[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide
   Show/Hide
C31H40N4O7
 5
1 IC50 = 30.5 nM
2 IC50 = 37.9 nM
3 IC50 = 39 nM
4 IC50 = 52 nM
5 IC50 = 450 nM
CP0086565
CHEMBL4441524
   Show/Hide
C31H43N3O7
 1
1 IC50 = 34 nM
CP0571152
[(1R)-2-(4-chlorophenyl)-1-[(2-phenylacetyl)amino]ethyl]boronic acid
   Show/Hide
C16H17BClNO3
 1
1 IC50 = 38 nM
CP0086566
(2S)-2-[[2-(azepan-1-yl)acetyl]amino]-4-methyl-N-[(2S)-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pentanamide
   Show/Hide
C35H48N4O5
 1
1 IC50 = 49 nM
CP0354051
(2S)-N'-tert-butyl-N-[(2S)-1-[(4-fluoronaphthalen-1-yl)methylamino]-3-methoxy-1-oxopropan-2-yl]-2-[(4-methylphenyl)sulfonylamino]butanediamide
   Show/Hide
C30H37FN4O6S
 1
1 IC50 = 56 nM
CP0151829
(2S)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide
   Show/Hide
C30H42N4O7
 1
1 IC50 = 83 nM
CP0572727
[(1R)-2-(3,4-dimethylphenyl)-1-[(2-phenylacetyl)amino]ethyl]boronic acid
   Show/Hide
C18H22BNO3
 1
1 IC50 = 85 nM
CP0575637
US10294246, Compound No. 14
   Show/Hide
C17H20BNO3
 1
1 IC50 = 91 nM
CP0573716
US10294246, Compound No. 29
   Show/Hide
C18H22BNO3
 1
1 IC50 = 130 nM
CP0577158
[(1R)-2-phenyl-1-[(2-phenylacetyl)amino]ethyl]boronic acid
   Show/Hide
C16H18BNO3
 1
1 IC50 = 160 nM
CP0564534
[(1R)-2-(1-benzofuran-3-yl)-1-[[(2S)-oxolane-2-carbonyl]amino]ethyl]boronic acid
   Show/Hide
C15H18BNO5
 1
1 IC50 = 190 nM
CP0575639
US10294246, Compound No. 73
   Show/Hide
C18H17BClNO4
 1
1 IC50 = 200 nM
CP0564530
US10294246, Compound No. 133
   Show/Hide
C18H19BClNO4
 1
1 IC50 = 610 nM
CP0550600
[(1R)-3-methyl-1-[(2-phenylacetyl)amino]butyl]boronic acid
   Show/Hide
C13H20BNO3
 1
1 IC50 = 1000 nM
CP0571392
[(1S)-2-(3,4-dimethylphenyl)-1-[(2-phenylacetyl)amino]ethyl]boronic acid
   Show/Hide
C18H22BNO3
 1
1 IC50 = 1200 nM
CP0261361
(2S)-N-[(2S)-1-[[(E,2S)-1-[4-(aminomethyl)phenyl]-4-methylsulfonylbut-3-en-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-2-[[(2S)-2-azido-3-phenylpropanoyl]amino]-4-methylpentanamide
   Show/Hide
C33H47N7O5S
 1
1 IC50 = 1800 nM
Clinical Information about the Protein
Target 1 ( Proteasome beta-8 (PS beta-8) )
Target Type Clinical trial Target
Disease 1 Target-related Disease  1
1 Multiple myeloma [ICD-11: 2A83]
Clinical Trial Drug(s) 1 Clinical Trial Drug  1
1 M3258 Phase 1
Multiple myeloma